{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:49:16Z","timestamp":1792068556828,"version":"4.4.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009562","name":"Berthold Leibinger Foundation Ditzingen, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung Stuttgart, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>In today\u2019s era of individualized precision medicine drug repurposing represents a promising approach to offer patients fast access to novel treatments. Apart from drug repurposing in cancer treatments, cardiovascular pharmacology is another attractive field for this approach. Patients with angina pectoris without obstructive coronary artery disease (ANOCA) report refractory angina despite standard medications in up to 40% of cases. Drug repurposing also appears to be an auspicious option for this indication. From a pathophysiological point of view ANOCA patients frequently suffer from vasomotor disorders such as coronary spasm and\/or impaired microvascular vasodilatation. Consequently, we carefully screened the literature and identified two potential therapeutic targets: the blockade of the endothelin-1 (ET-1) receptor and the stimulation of soluble guanylate cyclase (sGC). Genetically increased endothelin expression results in elevated levels of ET-1, justifying ET-1 receptor blockers as drug candidates to treat coronary spasm. sGC stimulators may be beneficial as they stimulate the NO-sGC-cGMP pathway leading to GMP-mediated vasodilatation.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1156456","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:11:22Z","timestamp":1686895882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug repurposing\u2014a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)"],"prefix":"10.3389","volume":"10","author":[{"given":"Johanna","family":"McChord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Mart\u00ednez","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Froebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Bekeredjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(15)60635-3","article-title":"Cancer and cardiovascular disease: more tightly linked than by chance","volume":"385","author":"Opie","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov Today"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.drudis.2022.04.001","article-title":"Repurposing drugs as COVID-19 therapies: a toxicity evaluation","volume":"27","author":"Ngan","year":"2022","journal-title":"Drug Discov Today"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1093\/eurheartj\/eht356","article-title":"Cardiovascular disease in Europe: epidemiological update","volume":"34","author":"Nichols","year":"2013","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.rdc.2010.02.002","article-title":"Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment","volume":"36","author":"Kaplan","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa0907272","article-title":"Low diagnostic yield of elective coronary angiography","volume":"362","author":"Patel","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/eurheartj\/ehr009","article-title":"Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain?","volume":"32","author":"Johnston","year":"2011","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jacc.2011.05.019","article-title":"Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography","volume":"58","author":"Douglas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jacc.2008.04.050","article-title":"Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study","volume":"52","author":"Ong","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0140-6736(97)07329-7","article-title":"Angina pectoris caused by coronary microvascular spasm","volume":"351","author":"Mohri","year":"1998","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1161\/01.CIR.0000116601.58103.62","article-title":"Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X)","volume":"109","author":"Kaski","year":"2004","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1093\/eurheartj\/ehaa503","article-title":"An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group","volume":"41","author":"Kunadian","year":"2020","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcin.2019.11.001","article-title":"1-Year Outcomes of angina management guided by invasive coronary function testing (CorMicA)","volume":"13","author":"Ford","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.jcin.2020.05.009","article-title":"Long-Term follow-up in patients with stable angina and unobstructed coronary arteries undergoing intracoronary acetylcholine testing","volume":"13","author":"Seitz","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/MCA.0000000000000876","article-title":"Prognostic implications of coronary artery stenosis and coronary spasm in patients with stable angina: 5-year follow-up of the abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries (ACOVA) study","volume":"31","author":"Seitz","year":"2020","journal-title":"Coron Artery Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.3390\/jcm9092880","article-title":"Coronary microvascular dysfunction","volume":"9","author":"Vancheri","year":"2020","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cpt.336","article-title":"Clinical relevance of cyclic GMP modulators: a translational success story of network pharmacology","volume":"99","author":"Oettrich","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/FJC.0000000000000744","article-title":"cGMP signaling in cardiovascular diseases: linking genotype and phenotype","volume":"75","author":"Dang","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","volume":"191","author":"Schmidt","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCRESAHA.109.198234","article-title":"Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation","volume":"105","author":"Meurer","year":"2009","journal-title":"Circ Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J Hypertens"},{"key":"B32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e43433","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS ONE"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jaccas.2020.11.043","article-title":"Repurposing riociguat for treatment of refractory angina resulting from coronary spasm","volume":"3","author":"Pereyra","year":"2021","journal-title":"Case Reports"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e001977","DOI":"10.1161\/CIRCGEN.117.001977","article-title":"Druggability of coronary artery disease risk loci","volume":"11","author":"Tragante","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1006\/pupt.1998.0126","article-title":"Endothelin-1: a mediator of pulmonary hypertension?","volume":"11","author":"MacLean","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1164\/ajrccm.156.2.9607123","article-title":"Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist","volume":"156","author":"Park","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1476-5381.1995.tb15868.x","article-title":"Acute pro-inflammatory actions of endothelin-1 in the Guinea-pig lung: involvement of ETA and ETB receptors","volume":"115","author":"Filep","year":"1995","journal-title":"Br J Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.109.900191","article-title":"Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management","volume":"121","author":"Lanza","year":"2010","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijcard.2003.06.025","article-title":"Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow","volume":"97","author":"Pekdemir","year":"2004","journal-title":"Int J Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/cvr\/cvx103","article-title":"Enhanced endothelin-1\/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy","volume":"113","author":"Tsai","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.cell.2017.06.049","article-title":"A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression","volume":"170","author":"Gupta","year":"2017","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1000 Genomes\u2013based genome-wide association meta-analysis of coronary artery disease","volume":"2015","author":"Nikpay","year":"","journal-title":"Nat Genet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/eurheartj\/ehz915","article-title":"Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction","volume":"41","author":"Ford","year":"2020","journal-title":"Eur Heart J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ahj.2020.07.007","article-title":"Rationale and design of the medical research council\u2019s precision medicine with Zibotentan in microvascular angina (PRIZE) trial","volume":"229","author":"Morrow","year":"2020","journal-title":"Am Heart J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.5543\/tkda.2013.37998","article-title":"A new hope in the treatment of coronary vasospasm: bosentan","volume":"41","author":"G\u00fcl","year":"2013","journal-title":"Turk Kardiyol Dern Ars"},{"key":"B52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2143\/AC.64.3.2038032","article-title":"Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm","volume":"64","author":"Vermeltfoort","year":"2009","journal-title":"Acta Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000313365","article-title":"First report of the successful use of bosentan in refractory vasospastic angina","volume":"116","author":"Krishnan","year":"2010","journal-title":"Cardiology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1158\/0008-5472.379.65.2","article-title":"Cellular targets of gefitinib","volume":"65","author":"Brehmer","year":"2005","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Molina","year":"2013","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.2013.1","article-title":"Computational drug repositioning: from data to therapeutics","volume":"93","author":"Hurle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/clpt.2009.103","article-title":"Systematic evaluation of drug-disease relationships to identify leads for novel drug uses","volume":"86","author":"Chiang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1021\/jm300576q","article-title":"Predicting new indications for approved drugs using a proteochemometric method","volume":"55","author":"Dakshanamurthy","year":"2012","journal-title":"J Med Chem"},{"key":"B62","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"B63","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fchem.2018.00138","article-title":"Reverse screening methods to search for the protein targets of chemopreventive compounds","volume":"6","author":"Huang","year":"2018","journal-title":"Front Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4155\/fmc.13.207","article-title":"Reverse docking: a powerful tool for drug repositioning and drug rescue","volume":"6","author":"Kharkar","year":"2014","journal-title":"Future Med Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/nbt.2758","article-title":"Rational drug repositioning by medical genetics","volume":"31","author":"Wang","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt.2151","article-title":"Use of genome-wide association studies for drug repositioning","volume":"30","author":"Sanseau","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1755-8794-8-S2-S1","article-title":"Novel therapeutics for coronary artery disease from genome-wide association study data","volume":"8","author":"Grover","year":"2015","journal-title":"BMC Med Genomics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e33174","DOI":"10.1371\/journal.pone.0033174","article-title":"Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS ONE"},{"key":"B69","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3259","article-title":"Understanding multicellular function and disease with human tissue-specific networks","volume":"47","author":"Greene","year":"2015","journal-title":"Nat Genet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1093\/hmg\/ddw160","article-title":"Pathway and network-based strategies to translate genetic discoveries into effective therapies","volume":"25","author":"Greene","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drudis.2011.09.019","article-title":"Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups","volume":"17","author":"Cavalla","year":"2012","journal-title":"Drug Discov Today"},{"key":"B72","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrg3208","article-title":"Mining electronic health records: towards better research applications and clinical care","volume":"13","author":"Jensen","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1038\/srep08580","article-title":"Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records","volume":"5","author":"Paik","year":"2015","journal-title":"Sci Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/483544a","article-title":"Drug discovery: cell lines battle cancer","volume":"483","author":"Weinstein","year":"2012","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/ije\/dyw087","article-title":"A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults","volume":"45","author":"Millwood","year":"2016","journal-title":"Int J Epidemiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/529009a","article-title":"China Embraces precision medicine on a massive scale","volume":"529","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.1837","article-title":"Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm","volume":"29","author":"Wicks","year":"2011","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1156456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:11:27Z","timestamp":1686895887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1156456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":80,"alternative-id":["10.3389\/fcvm.2023.1156456"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1156456","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1156456"}}